Reach Us +441467840001
Current SAR On HIV: The Flow From Phenotypic Assays Via Medicinal Chemistry To In Silico Design | 24144
ISSN: 2161-0444

Medicinal Chemistry
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Current SAR on HIV: The flow from phenotypic assays via medicinal chemistry to in silico design

3rd International Conference on Medicinal Chemistry & Computer Aided Drug Designing

Peter Teriete

ScientificTracks Abstracts: Med Chem

DOI: 10.4172/2161-0444.S1.011

Cellular phenotypic assays provide a powerful method to investigate the capability of small molecules to perturb important biological processes. A small library of dihydropyrimidinone (DHPM) derivatives prepared using continuous flow chemistry was tested in phenotypic assays and provided a hit that inhibited the replication of the human immunodeficiency virus (HIV) in cells. Investigation of the structure activity relationships (SAR) around this compound using flow synthesis methodology to rapidly and efficiently generate analogues led to the identification of potent HIV replication inhibitors with promising drug-like properties. Importantly, some of the lead structures inhibit the replication of a drug resistant strain of HIV. Mechanistic studies coupled with 3D in silico modeling suggest that these compounds exert their effects by inhibiting the viral RT enzyme.
Peter Teriete completed his DPhil in biophysics from the University of Oxford, UK and completed postdoctoral studies at the Sanford-Burnham Institute for Medical Research, La Jolla, CA. As a project manager there, he utilizes his extensive expertise in structural biochemistry and biophysical characterization in the design and development of novel small molecule inhibitors of HIV as well as many other pathologies.